Kalaris Reports Third Quarter 2026 Financial Results and Provides Business Update
Globe Newswire•10/11/2026•07:30 ET
0
Key Highlights
- ➤Phase 1b/2 TH103 nAMD data shifted to 2H 2027 after manufacturing supply interruption
- ➤Kalaris (KLRS) completed KBI Biopharma technology transfer; test batches met Phase 3 specifications
- ➤$82.9 million cash, equivalents and securities expected to fund operations into 2028
- ➤Q3 net loss narrowed to $11.0 million from $11.9 million year over year
- ➤New TH103 batch expected in Q2 2027 after pilot-manufacturer batch failed aggregation specification
Expert Statements
Andrew Oxtoby, Chief Executive Officer of Kalaris Therapeutics
“Kalaris made meaningful progress in the third quarter”
Andrew Oxtoby, Chief Executive Officer of Kalaris Therapeutics
“We continue to enroll and dose nAMD patients in the ongoing Phase 1b/2 study.”
Andrew Oxtoby, Chief Executive Officer of Kalaris Therapeutics
“In addition to progressing the clinical trial, we have successfully completed the tech transfer to a new commercial-scale manufacturer, with initial test batches achieving the target specifications.”
Andrew Oxtoby, Chief Executive Officer of Kalaris Therapeutics
“Given the paramount importance of ensuring critical quality attributes at the scale required for Phase 3 and commercial supply, this was a significant accomplishment in Q3 and strengthens our confidence in our future clinical supply.”
Preliminary data from the ongoing Phase 1b/2 study of TH103 in nAMD is now expected in 2H 2027
Recently completed technology transfer from pilot to commercial-scale manufacturer with test batches meeting target specifications
Get started
Create a free account to read the full story.